GMAB Prakiraan wutah bathi resik saben saham kanggo taun ngarep genmab.com

Genmab A/S (GMAB) adheres to basic environmental standards, minimizing the ecological impact of its laboratories. The business relies on DuoBody, creating bispecific antibodies to protect long-term licensing streams. The valuation of forward net income growth rates confirms this potential, where this metric equals 33.60. Financial stability is based on royalties from partners for the implementation of innovative anti-tumor drugs.

GMAB: Prakiraan wutah bathi resik saben siji saham kanggo taun ngarep Genmab AS 04.07.2022 - 10.11.2026

Rincian metrik keuangan lan pasar genmab.com (GMAB)

- rega saham lan konsensus proyeksi valuasi:

Rega saham Genmab US|GMAB - Prakiraan konsensus analis

- data kapitalisasi pasar:

Nilai pasar Genmab|GMAB - Nilai Dipunlarasaken Utang lan Kas

- rincian nilai buku perusahaan:

Nilai Buku saben Saham Genmab|GMAB - Nilai Buku Bisnis|Rasio Kapitalisasi Pasar marang Nilai Buku genmab.com|GMAB - Aset Perusahaan

- indikator total utang lan likuiditas perusahaan:

Rasio Total Utang marang Ekuitas Genmab A/S|GMAB - Rasio silihan jangka dawa marang modal|Utang jangka cendhak marang modal Genmab|GMAB - Utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Genmab|GMAB - Tanggungan utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Genmab|Indikator likuiditas cepet genmab.com

- informasi bathi lan kelipatan valuasi:

GMAB - Bathi sawise mbayar pajeg|Proyeksi bathi mangsa ngarep Genmab A/S|GMAB - Nilai perusahaan marang bathi resik|Pangali Forward P/E Genmab A/S|GMAB - Rega marang bathi kanthi panyesuaian wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Genmab|GMAB - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Genmab|GMAB - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan genmab.com|GMAB - Dinamika bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Genmab A/S

Analisis fundamental perusahaan:Genmab US, GMAB

Investors are assessing the potential of Genmab A/S through the dynamics of future earnings. This metric measures the percentage change in expected net income per share for the following year relative to the current year. By analyzing the projected growth of net income per share for year n+1, one can see the calculated value of 33.60. For a biotech company with minimal environmental costs, this indicator reflects the efficiency of antibody development.

Perusahaan pesaing